Literature DB >> 18234989

Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium.

Karl G Csaky1, Elaine A Richman, Frederick L Ferris.   

Abstract

Mesh：

Year:  2008        PMID： 18234989     DOI： 10.1167/iovs.07-1132

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN： 0146-0404            Impact factor:   4.799


× No keyword cloud information.
  83 in total

Review 1.  Aging and vision.

Authors:  Cynthia Owsley
Journal:  Vision Res       Date:  2010-10-23       Impact factor: 1.886

2.  Glaucoma research community and FDA look to the future, II: NEI/FDA Glaucoma Clinical Trial Design and Endpoints Symposium: measures of structural change and visual function.

Authors:  Robert N Weinreb; Paul L Kaufman
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-10-04       Impact factor: 4.799

3.  Use of patient-reported outcomes in medical product development: a report from the 2009 NEI/FDA Clinical Trial Endpoints Symposium.

Authors:  Rohit Varma; Elaine A Richman; Frederick L Ferris; Neil M Bressler
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-12       Impact factor: 4.799

4.  Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications.

Authors:  Henry F Edelhauser; Cheryl L Rowe-Rendleman; Michael R Robinson; Daniel G Dawson; Gerald J Chader; Hans E Grossniklaus; Kay D Rittenhouse; Clive G Wilson; David A Weber; Baruch D Kuppermann; Karl G Csaky; Timothy W Olsen; Uday B Kompella; V Michael Holers; Gregory S Hageman; Brian C Gilger; Peter A Campochiaro; Scott M Whitcup; Wai T Wong
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-11       Impact factor: 4.799

5.  Association between retinal thickness measured by spectral-domain optical coherence tomography (OCT) and rod-mediated dark adaptation in non-exudative age-related maculopathy.

Authors:  Mark E Clark; Gerald McGwin; David Neely; Richard Feist; John O Mason; Martin Thomley; Milton F White; Bunyamin Ozaydin; Christopher A Girkin; Cynthia Owsley
Journal:  Br J Ophthalmol       Date:  2011-02-02       Impact factor: 4.638

6.  Topical dorzolamide for treatment of cystoid macular edema in patients with choroideremia.

Authors:  Mohamed A Genead; Jason J McAnany; Gerald A Fishman
Journal:  Retina       Date:  2012-04       Impact factor: 4.256

7.  Retinal pigment epithelial expression of complement regulator CD46 is altered early in the course of geographic atrophy.

Authors:  Susan D Vogt; Christine A Curcio; Lan Wang; Chuan-Ming Li; Gerald McGwin; Nancy E Medeiros; Nancy J Philp; James A Kimble; Russell W Read
Journal:  Exp Eye Res       Date:  2011-06-12       Impact factor: 3.467

8.  Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual cone-photoreceptor vision correlates with biochemical properties of the mutants.

Authors:  Samuel G Jacobson; Artur V Cideciyan; Igor V Peshenko; Alexander Sumaroka; Elena V Olshevskaya; Lihui Cao; Sharon B Schwartz; Alejandro J Roman; Melani B Olivares; Sam Sadigh; King-Wai Yau; Elise Heon; Edwin M Stone; Alexander M Dizhoor
Journal:  Hum Mol Genet       Date:  2012-10-03       Impact factor: 6.150

Review 9.  Neuroprotection for treatment of glaucoma in adults.

Authors:  Dayse F Sena; Kristina Lindsley
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

10.  Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis.

Authors:  Tien Y Wong; Mkaya Mwamburi; Ronald Klein; Michael Larsen; Harry Flynn; Marisol Hernandez-Medina; Gayatri Ranganathan; Barbara Wirostko; Andreas Pleil; Paul Mitchell
Journal:  Diabetes Care       Date:  2009-12       Impact factor: 17.152
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.